tirzepatide in powder form 99%, CasNo.2023788-19-2 TS BIOTECHNOLOGY INC United States A new Science Perspective Sample collection:Home kit MEDICINES

tirzepatide in powder form 99%, CasNo.2023788-19-2 TS BIOTECHNOLOGY INC United States A new Science Perspective Sample collection:Home kit MEDICINES

A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.

Abbreviations: ACR=American College of Rheumatology

MEDICINES

Sample collection:Home kit

Phase 2 results (48 weeks): 1mg dose: 8.7% average weight loss 4mg dose: 17.1% average weight loss 8mg dose: 22.8% average weight loss 12mg dose: 24.2% average weight loss Placebo: 2.1% average weight loss These numbers came from a 48-week study period, six months shorter than the 72-week SURMOUNT trials